Molecular and Cell Biology Research Center (MCBRC), Hemoglobinopathy Institute, Mazandaran University of Medical Sciences, Sari, Iran; Molecular and Cell Biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Gastrointestinal Cancer Research Center, Non-communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.
Transpl Immunol. 2022 Dec;75:101732. doi: 10.1016/j.trim.2022.101732. Epub 2022 Oct 31.
Inactivated (killed) vaccines against COVID-19 have been widely used for the control of the pandemic condition. We performed a systematic and meta-analysis review of randomized, double-blind, placebo-controlled trials of the immunogenicity of inactivated vaccines against SARS-CoV-2 in healthy individuals.
In the present study, all research and evidence were extracted from the available online databases. Two researchers randomly evaluated the assessment of the research sensitivity. Finally, after quality assessment and regarding the specific inclusion and exclusion criteria, the eligible articles were entered for meta-analysis. The heterogeneity between the results of the studies was measured using test statistics (Cochran's Q) and the I index. The forest plots illustrated the point and pooled estimates with 95% confidence intervals (crossed lines). All statistical analyses were performed using Comprehensive meta-Analysis V.2 software.
This meta-analysis included six primary studies investigating the immunogenicity of inactivated vaccines against SARS-CoV-2 in healthy individuals. According to the pooled prevalence (95% confidence interval), neutralizing antibody responses 28 days after receiving the second dose regarding different ages and micrograms per dose was 95.50% (CI: 93.2-97.1%). Our results showed that antibody levels were higher in the 6 μg group than in other groups. 98.3% (CI: 94.2-99.5%).
Since the rapid development of vaccinations has sparked widespread public anxiety regarding vaccine efficacy. Governments and unvaccinated individuals, particularly those with vaccination reluctance, will be interested in and benefit from the findings of this systematic study.
针对 COVID-19 的灭活(杀死)疫苗已被广泛用于控制大流行情况。我们对健康个体中针对 SARS-CoV-2 的灭活疫苗的免疫原性进行了系统的、荟萃分析的随机、双盲、安慰剂对照试验的综述。
在本研究中,所有研究和证据均从可用的在线数据库中提取。两位研究人员随机评估了研究敏感性的评估。最后,在进行质量评估并考虑具体的纳入和排除标准后,合格的文章将被纳入荟萃分析。使用检验统计量(Cochran's Q)和 I 指数来衡量研究结果之间的异质性。森林图用 95%置信区间(交叉线)说明了点和汇总估计值。所有统计分析均使用 Comprehensive meta-Analysis V.2 软件进行。
该荟萃分析包括六项针对健康个体中针对 SARS-CoV-2 的灭活疫苗的免疫原性的主要研究。根据不同年龄和每剂微克数的第二剂后 28 天的汇总流行率(95%置信区间),中和抗体反应为 95.50%(CI:93.2-97.1%)。我们的结果表明,6μg 组的抗体水平高于其他组。98.3%(CI:94.2-99.5%)。
由于疫苗接种的快速发展引发了公众对疫苗效力的广泛焦虑。政府和未接种疫苗的人,特别是那些对疫苗犹豫不决的人,将对这项系统研究的发现感兴趣并从中受益。